WO2025223458 - CYP11A1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/223458
Publication Date
30.10.2025
International Application No.
PCT/CN2025/090673
International Filing Date
23.04.2025
Title **
[English]
CYP11A1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
[French]
INHIBITEUR DE CYP11A1, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
一种CYP11A1抑制剂、其制备方法及其应用
Applicants **
SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD.
Inventors
HUANG, Minhao
QIU, Shuwan
WU, Yuhang
Priority Data
202410495469.0
23.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2593 | |
| EPO | Filing, Examination, Granting | 20300 | |
| Japan | Filing, Examination, Granting | 2580 | |
| South Korea | Filing, Examination, Granting | 2965 | |
| USA | Filing, Examination, Granting | 6340 |
Total:
34,778
Contact Us
Abstract[English]
The present application relates to a compound represented by formula (I), and the compound can inhibit steroid hormone-dependent disorders and diseases of CYP11A1. The present application further comprises a pharmaceutical composition comprising the compound represented by formula (I) and a method for treating a condition related to CYP11A1 activity.[French]
La présente invention concerne un composé représenté par la formule (I), et le composé peut inhiber des troubles dépendant de l'hormone stéroïdienne et des maladies de CYP11A1. La présente invention concerne en outre une composition pharmaceutique comprenant le composé représenté par la formule (I) et un procédé de traitement d'un état lié à l'activité de CYP11A1.[Chinese]
本申请涉及一种式(I)所示化合物，该化合物能够抑制CYP11A1的类固醇激素依赖性病症和疾病。本申请还包括包含式(I)所述化合物的药物组合物及用于治疗与CYP11A1活性相关的病况的方法。